개요
디지털 흡입기는 전자기기와 연동하여 환자의 건강 상태를 매일 확인할 수 있는 호흡 보조 장치입니다. 천식이나 폐쇄성 질환과 같은 호흡기 질환을 앓고 있는 사람들에게 특히 유용합니다. 이 흡입기의 센서는 사용자가 매일 적절한 시간에 약을 복용하도록 상기시켜 줍니다.
디지털 흡입기 건강 시스템은 전기 기계 센서와 마이크로 일렉트로닉스를 사용하여 흡입기 작동을 모니터링합니다. 일부 가젯에는 연결된 스마트 폰, 환자와 통신하는 모바일 앱, 클라우드 서버 및 의사가 대시 보드 데이터를 볼 수있는 포털이 포함됩니다.
일부 디지털 흡입기는 오염이나 꽃가루 수준을 측정하거나 환자가 잊어버렸을 때 알람을 울려주는 제품도 있습니다. 스마트 흡입기는 환자가 복용을 잊었거나 여러 번 반복해서 복용하는 것을 알려주어 환자가 제때에 자동으로 쉽게 복용할 수 있도록 주의를 환기시킵니다.
시장 역학: 시장 촉진요인과 시장 억제요인
호흡기 질환의 유병률 증가
호흡기 질환의 증가는 예측 기간 동안 시장 성장의 주요 촉진요인 중 하나입니다. 천식 및 COPD와 같은 호흡기 질환의 증가 이후 디지털 흡입기 장치의 사용은 실제로 시장 성장을 증가시키는 데 빠르게 사용되고 있습니다.
예를 들어, 질병관리본부에 따르면, COPD는 약 2억 명이 앓고 있으며, 매년 320만 명이 사망하는 것으로 추정되며, 전 세계 사망 원인 중 3위를 차지하고 있습니다.
천식은 가장 흔한 비감염성 질환 중 하나로 전 세계 2억 6,200만 명이 앓고 있으며, 2022년에는 약 2,200만 명이 폐암에 걸려 1,800만 명이 사망할 것으로 예상되며, 폐암은 전 세계 암 사망자 4명 중 1명이 폐암으로 사망할 것으로 예상됩니다. 하기도 감염 또는 폐렴은 주로 중저소득 국가(LMICs)에서 매년 2,400만 명 이상이 사망하는 주요 사망 원인이며, COVID-19는 전 세계적으로 폐렴으로 인한 사망자 수를 크게 증가시키고 있습니다.
또한, 흡입기 기술 발전, 데이터 기반 건강 관리, 노인 인구의 유병률 증가, 원격 의료의 증가 등은 예측 기간 동안 시장을 더욱 견인할 것입니다.
시장 역학: 억제요인
예측 기간 동안 시장 성장을 저해하는 여러 가지 요인이 있습니다. 예를 들어, 약물 비용의 증가, 장치와 관련된 높은 비용, 개인 정보 보호 및 데이터 보안 문제, 규제 장애물, 천식에 사용할 수 있는 고급 치료 및 장치에 대한 사람들의 인식 부족 등이 있습니다.
목차
제1장 조사 방법과 조사 범위
제2장 정의와 개요
제3장 주요 요약
제4장 시장 역학
제5장 산업 분석
- Porter's Five Forces 분석
- 공급망 분석
- 가격 분석
- 규제 분석
- 러시아·우크라이나 전쟁의 영향 분석
- DMI 의견
제6장 COVID-19 분석
제7장 디바이스 유형별
제8장 용도별
제9장 유형별
제10장 유통 채널별
제11장 지역별
- 북미
- 유럽
- 남미
- 아시아태평양
- 중동 및 아프리카
제12장 경쟁 상황
- 경쟁 시나리오
- 시장 상황/점유율 분석
- M&A 분석
제13장 기업 개요
- Novartis International AG
- 기업 개요
- 제품 포트폴리오와 설명
- 재무 개요
- 주요 발전
- Propeller Health
- H&T Presspart Manufacturing Ltd
- AptarGroup Inc
- Amiko Digital Health Limited
- Trudell Medical UK Limited
- ReciPharm
- Sensirion
- Teva Pharmaceuticals
- Cohero Health, Inc
제14장 부록
ksm
Overview
Digital dose inhalers are breathing aids that can be linked to electronic devices to check on a patient's health every day. These are especially helpful for people with respiratory diseases like asthma or obstructive diseases. Sensors in these inhalers prompt the user to take medicine at the appropriate times each day.
Digital dose inhaler health systems use electromechanical sensors and microelectronics to monitor inhaler actuation. Some gadgets include a linked smartphone, a mobile app that communicates with the patient, a cloud server, and a portal for the physician to see dashboard data.
Some digital dose inhalers can measure pollution or pollen levels or alarm patients if they forget them. Smart inhalers notify patients of missed or repeated doses and remind them to take their dosages on time, automatically, and easily.
Market Dynamics: Drivers and Restraints
Rise in prevalence of respiratory diseases
The rise in the prevalence of respiratory disease is one of the key drivers that helps the market to grow during the forecast period. Since the rise in respiratory diseases like asthma and COPD the use of digital dose inhaler devices is often used rapidly which indeed will increase the market growth.
For instance, according to the Centers for Disease Control and Prevention COPD affects an estimated 200 million people, with 3.2 million dying each year, making it the third-leading cause of mortality globally.
Asthma is one of the most common noncommunicable illnesses, impacting 262 million people worldwide. With almost 2.2 million new instances of lung cancer expected in 2022 and 1.80 million fatalities, lung cancer accounts for one in every four cancer deaths worldwide. Lower respiratory tract infection or pneumonia is a prominent cause of death, accounting for more than 2.4 million fatalities each year, primarily in low and middle-income countries (LMICs). COVID-19 has significantly increased pneumonia fatalities worldwide.
Furthermore, technological advancements in technological advancements in inhalers, Data-Driven Healthcare, the rise in the prevalence of the geriatric population, and rise in the telemedicine's and others will further drive the market during the forecast period.
Market Dynamics: Restraint
Many restraint factors hampers the market growth during the forecast period some of the mare like, increasing medication cost and high cost associated with devices, privacy and data security concerns, regulatory hurdles, and lack of awareness among people regarding advanced treatment and devices available for asthma are going to impede the market growth.
Segment Analysis
The global digital dose inhalers is segmented based on product type, type, application, type, distribution channel and region.
The metered-dose inhaler from the device type segment accounted for approximately 41.2% of the market share
The metered-dose inhaler from the device type segment accounted for 41.2% and it is expected to be dominated during the forecast period. A metered-dose inhaler has a pressurized canister of medication that fits into a mouthpiece. In most instances, a dose of medication is released into your lungs by pushing the canister into the mouthpiece. Another type releases medication automatically when you inhale. Some metered-dose inhalers have counters that track how many doses remain.
For instance, on July 2023, Hormosan Pharma GmbH (Hormosan), Lupin's wholly-owned subsidiary in Germany, stated that they have been launched Luforbec 100/6 (beclometasone 100µg / for motel 6µg), a fix combination in a pressurized metered dose inhaler (pMDI) for the treatment of adult asthma and chronic obstructive pulmonary disease (COPD) in Germany.
Moreover, on February 8 2022, Aptar Pharma, a global leader in drug delivery systems, services and active material science solutions, stated the launch of HeroTracker Sense, a novel digital respiratory health solution that transforms a standard metered dose inhaler (pMDI) into a smart connected healthcare device.
HeroTracker Sense is designed to help improve the lives of patients around the world suffering from chronic respiratory diseases such as asthma, COPD, Cystic Fibrosis and other respiratory conditions caused by COVID-19, to track their usage and facilitate improved adherence to their prescribed therapy.
Geographical Analysis
North America accounted for approximately 38.4% of the market share in 2022
North America is estimated to hold about 38.4% of the total market share throughout the forecast period, owing to rigorous research and development activities and increased awareness regarding the currently available hi-tech respiratory devices. In addition, an upsurge in the prevalence of respiratory conditions among both the pediatric and elderly populations will boost the market growth over the forecast years.
For instance, in September 2020, Teva Pharmaceuticals launched the AirDuo Digihare and ArmonAir Digihaler inhalation powder, two digital maintenance inhalers for patients with asthma.
COVID-19 Impact Analysis
COVID-19 had a substantial impact on the global digital dose inhalers market importantly on asthma for instance, according to the article titled "Risk of serious COVID-19 outcomes among adults with asthma in Scotland: a National Incident Cohort Study" published in January 2022 adults with asthma were found to be at an increased risk of COVID-19 hospital admission compared with those without asthma conditions. Thus, increasing cases of COVID-19 are raising the cases of respiratory disorders which generates the need for digital dose inhalers.
Competitive Landscape
The major global players in the digital dose inhalers market include: Novartis International AG, Propeller Health, H&T Presspart Manufacturing Ltd, AptarGroup Inc, Amiko Digital Health Limited, Trudell Medical UK Limited, ReciPharm, Sensirion, Teva Pharmaceuticals, Cohero Health, Inc and among others.
Key Developments
- In February 2022, AstraZeneca and Honeywell partnered to develop next-generation respiratory inhalers using the propellant HFO-1234ze, which has up to 99.9% less global warming potential than propellants currently used in respiratory medicines.
- In October 2020, Zydus launched a pressurised Metered Dose Inhaler for COPD patient.
Why Purchase the Report?
- To visualize the global digital dose inhalers market segmentation-based device type, application, type, distribution channel and region as well as understand key commercial assets and players.
- Identify commercial opportunities by analyzing trends and co-development
- Excel data sheet with numerous data points of digital dose inhalers market-level with all segments.
- PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
- Product mapping available as excel consisting of key products of all the major players.
The global digital dose inhalers market report would provide approximately 69 tables, 70 figures, and 185 Pages.
Target Audience 2023
- Manufacturers/ Buyers
- Industry Investors/Investment Bankers
- Research Professionals
- Emerging Companies
Table of Contents
1. Methodology and Scope
- 1.1. Research Methodology
- 1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
- 3.1. Snippet by Device Type
- 3.2. Snippet by Application
- 3.3. Snippet by Type
- 3.4. Snippet by Distribution Channel
- 3.5. Snippet by Region
4. Dynamics
- 4.1. Impacting Factors
- 4.1.1. Driver
- 4.1.1.1. Rise in the prevalence of respiratory diseases
- 4.1.1.2. Rise in the technology advancements
- 4.1.2. Restraints
- 4.1.3. Opportunity
- 4.1.4. Impact Analysis
5. Industry Analysis
- 5.1. Porter's Five Force Analysis
- 5.2. Supply Chain Analysis
- 5.3. Pricing Analysis
- 5.4. Regulatory Analysis
- 5.5. Russia-Ukraine War Impact Analysis
- 5.6. DMI Opinion
6. COVID-19 Analysis
- 6.1. Analysis of COVID-19
- 6.1.1. Scenario Before COVID
- 6.1.2. Scenario During COVID
- 6.1.3. Scenario Post COVID
- 6.2. Pricing Dynamics Amid COVID-19
- 6.3. Demand-Supply Spectrum
- 6.4. Government Initiatives Related to the Market During Pandemic
- 6.5. Manufacturers Strategic Initiatives
- 6.6. Conclusion
7. By Device Type
- 7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
- 7.1.2. Market Attractiveness Index, By Device Type
- 7.2. Metered Dose Inhalers *
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Dry Powder Inhalers
8. By Application
- 8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
- 8.2. Asthma *
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. COPD
- 8.4. Others
9. By Type
- 9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 9.1.2. Market Attractiveness Index, By Type
- 9.2. Branded *
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 9.3. Generic
10. By Distribution Channel
- 10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 10.1.2. Market Attractiveness Index, By Distribution Channel
- 10.2. Hospital Pharmacies *
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 10.3. Retail Pharmacies
- 10.4. Online Pharmacies
11. By Region
- 11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
- 11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.2.7.1. U.S.
- 11.2.7.2. Canada
- 11.2.7.3. Mexico
- 11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.3.7.1. Germany
- 11.3.7.2. UK
- 11.3.7.3. France
- 11.3.7.4. Italy
- 11.3.7.5. Spain
- 11.3.7.6. Rest of Europe
- 11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.4.7.1. Brazil
- 11.4.7.2. Argentina
- 11.4.7.3. Rest of South America
- 11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
- 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
- 11.5.7.1. China
- 11.5.7.2. India
- 11.5.7.3. Japan
- 11.5.7.4. Australia
- 11.5.7.5. Rest of Asia-Pacific
- 11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Device Type
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
12. Competitive Landscape
- 12.1. Competitive Scenario
- 12.2. Market Positioning/Share Analysis
- 12.3. Mergers and Acquisitions Analysis
13. Company Profiles
- 13.1. Novartis International AG
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
- 13.2. Propeller Health
- 13.3. H&T Presspart Manufacturing Ltd
- 13.4. AptarGroup Inc
- 13.5. Amiko Digital Health Limited
- 13.6. Trudell Medical UK Limited
- 13.7. ReciPharm
- 13.8. Sensirion
- 13.9. Teva Pharmaceuticals
- 13.10. Cohero Health, Inc
LIST NOT EXHAUSTIVE
14. Appendix
- 14.1. About Us and Services
- 14.2. Contact Us
